Skip to main content

Market Overview

Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms

Share:
Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms

Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year.

  • The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing, a whopping 48% increase over the same period in 2020.
  • After debuting with approval in adult PNH in late 2018, Ultomiris joined the blockbuster club in 2020 with $1.08 billion in sales.
  • The older Soliris continued to deliver and posted first-half sales of $2.1 billion, a 5% Y/Y increase. 
  • Overall revenues turned out to about $3.33 billion for the first half, a 15% increase over the $2.89 billion a year ago.
  • Recently, Alexion announced topline results from Ultomiris Phase 3 study evaluating Ultomiris in generalized myasthenia. 
  • Price Action: ALXN shares are up 1.34 at $181.85 during the market session on the last check Tuesday.
 

Related Articles (ALXN + AZN)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Earnings M&A News Guidance Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com